Graft Versus Host Disease: How You and I Diagnose it



Joel K. Greenson, M.D.

Biology of Blood and Marrow Transplantation 12:31-47 (2006) © 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0002\$32.00/0 doi:10.1016/j.bbmt.2005.10.023



Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report

Howard M. Shulman, David Kleiner, Stephanie J. Lee, Thomas Morton, Steven Z. Pavletic, Evan Farmer, Margaret Moresi, Soel Greenson, Anne Janin, Marin, Martin, George McDonald, Mary E. D. Flowers, Maria Turner, Jane Atkinson, Jay Lefkowitch, M. Kay Washington, Victor G. Prieto, Stella K. Kim, Zsolt Argenyi, A. Hafeez Diwan, Kashid, Kim Hiatt, Martin, Stella K. Kim, Georgia B. Vogelsang


¹Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington; ²National Cancer Institute, National Institutes of Health, Bethesda, Maryland; ³Dana-Farber Cancer Institute, Boston, Massachusetts; ⁴University of Washington School of Dentistry, Seattle, Washington; ⁵Johns Hopkins University School of Medicine, Baltimore, Maryland; ⁶University of Michigan Hospitals, Ann Arbor, Michigan; ⁷Hospital Saint Louis, Paris, France; ⁸National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland; ⁹Columbia University, New York, New York; ¹⁰Vanderbilt University, Nashville,

What is GVHD?

- To a Clinician it can be diarrhea, nausea, vomiting, skin rash, dry or itchy eyes, or jaundice
- To a Pathologist GVHD = Apoptosis, but Apoptosis does not = GVHD
- Infections, medications, bowel preparations and chemotherapy can all induce apoptosis identical to GVHD


What is Apoptosis?

- According to Wikipedia it is the process of programmed cell death
 - 20-30 billion cells die via apoptosis every day (this is normal)
- The term is Greek for dropping off (like petals dropping off of a flower)
- A large number of complex pathways involving TNF, Fas, BAX, BCL-2 and numerous cytokines control apoptosis




Mimics of GVHD

- Bowel Preparations
- Chemo/radiation therapy
 - Can't distinguish until day 21
- Drugs
 - Mycophenolate
 - NSAIDs
 - Proton Pump Inhibitors (PPI)
- Infections




Mycophenolate Mofetil (CellCept)

- Immunosuppressive drug used primarily in organ transplantation
 - Now being tried for inflammatory/autoimmune diseases such as IBD, Arthritis, Myasthenia
 - Used to treat GVHD
- Has a pattern of colitis that resembles GVHD or ischemia.
- Stomach and small bowel can also be involved



Number of Eosinophils / 5 HPF



Histologic Features in Colon Biopsies Can Discriminate Mycophenolate From GVHD-induced Colitis


Kremena V. Star, MD, PhD,* Vincent T. Ho, MD,† Helen H. Wang, MD,‡ and Robert D. Odze, MD, FRCPC*

Abstract: Mycophenolate mofetil (MMF) is a T-cell inhibitor frequently used in the treatment of acute allograft rejection. MMF may cause colitis that clinically and histologically resembles graft-versus-host disease (GVHD). The aim of this study was to evaluate a wide range of histologic features that may help differentiate MMF from GVHD-induced colitis and to validate significant features on a cohort of bone marrow transplant patients who were also taking MMF as part of their immunosuppressive regimen and developed a diarrheal illness due to colitis. Routinely processed colonic biopsies from 17 patients with MMF colitis and 40 patients with GVHD-induced colitis


predictive values of 76%, 93%, 81%, and 90%, respectively, for identification of MMF colitis. On the basis of these data, we conclude that a variety of histologic features, in particular, eosinophils > 15 per 10 HPF, lack of endocrine cell aggregates in the lamina propria, and lack of apoptotic microabscesses, can be used by pathologists to help separate MMF from GVHD-induced colitis in routine clinical practice.

Key Words: graft-versus-host disease, drug-induced colitis, toxic colitis, eosinophils, apoptosis, differential diagnosis

(Am J Surg Pathol 2013;37:1319-1328)





GVHD with numerous eosinophils



Infections and Apoptosis

- CMV
- Adenovirus
- HIV
- Cryptosporidia
- Bacteria?
 - Usually neutrophils/crypt abscess





MS Art - Grading Rubric

Name: Adam R Project: Graffiti Lettering Lurge, overlapping (3) 3 pts Placement of *2. Shadows (3) ___pts 3. Use of Color (3) 3 pts ** *4. Craftsmanship (3) 2 pts sub-total ____pts (adjusted + pts = 10 pts) ÷ weight of ___ = ___ total points * Shadows need to be consistent. ** Erase quidelines. (41 pt. for staying late to finish)

Grade -

Grading Scale for Art

12 points 11 points 10 points 9 points B+ 8 points B 7 points B-6 points C+ 5 points C 4 points 3 points D+ 2 points D 1 point D-F 0 points

Points may be adjusted for behavior, attitude and appropriate use of time.

GVHD Grading Scheme

GVHD GRADE PATHOLOGY


SCATTERED APOPTOSIS

II APOPTOSIS OF COMPLETE CRYPT

III LOSS OF CRYPTS


IV DENUDED MUCOSA

Lerner KG, et al. Transplant Proc 1974;6:367–371



Grade I GVHD

Grade II GVHD



Grade III GVHD

Grade IV GVHD

Biology of Blood and Marrow Transplantation 12:31-47 (2006) © 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0002\$32.00/0 doi:10.1016/j.bbmt.2005.10.023




Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report


Howard M. Shulman, David Kleiner, Stephanie 7. Lee, Thomas Morton, Steven Z. Pavletic, 2 Evan Farmer, ⁵ 7. Margaret Moresi, ⁵ 7oel Greenson, ⁶ A Mary E. D. Flowers, Maria Turner, 7 Jane Atkinson, 8 Victor G. Prieto, 11 Stella K. Kim, 11 Zsolt Argenyi, 12 A. Dan Couriel, 11 Kirk Schultz, 14 Sharon Hymes, 11 Georg

¹Fred Hutchinson Cancer Research Center, University of Wa ²National Cancer Institute, National Institutes of Health, Bet Boston, Massachusetts; ⁴University of Washington School of University School of Medicine, Baltimore, Maryland; ⁶University ⁷Hospital Saint Louis, Paris, France; ⁸National Institute of D Health, Bethesda, Maryland; ⁹Columbia University, New Yor


Recommended sign out:

- No GVHD
- Possible GVHD
- Consistent with GVHD
- GVHD





How do you grade GVHD?





Biology of Blood and Marrow Transplantation

journal homepage: www.bbmt.org



Report

NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report



Howard M. Shulman ¹, Diana M. Cardona ², Joel K. Greenson ³, Sangeeta Hingorani ^{1,4,5}, Thomas Horn ⁶, Elisabeth Huber ⁷, Andreas Kreft ⁸, Thomas Longerich ⁹, Thomas Morton ⁴, David Myerson ^{1,10}, Victor G. Prieto ¹¹, Avi Rosenberg ¹², Nathaniel Treister ¹³, Kay Washington ¹⁴, Mirjana Ziemer ¹⁵, Steven Z. Pavletic ¹⁶, Stephanie J. Lee ¹, Mary E.D. Flowers ¹, Kirk R. Schultz ¹⁷, Madan Jagasia ¹⁸, Paul J. Martin ¹, Georgia B. Vogelsang ¹⁹, David E. Kleiner ^{11,*}

Recommended sign out:

- 1. Negative for GVHD
- 2. Possible GVHD
- 3. Likely GVHD

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washingto

² Department of Pathology, Duke University Medical Center, Durham, North Carolina

³ Department of Pathology, University of Michigan, Ann Arbor, Michigan

⁴ Departments of Pediatrics, Gastroenterology and Pathology, University of Washington,

⁵ Seattle Children's Hospital, Seattle, Washington

⁶ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts

⁷ Institute of Pathology, University of Regensburg, Regensburg, Germany

⁸ Institute of Pathology, University Medical Center Mainz, Mainz, Germany

⁹ Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany

¹⁰ Department of Pathology, University of Washington, Seattle, Washington

¹¹ Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas



Minimum Criteria for Grade 1 GVHD

